Outlook Therapeutics, Inc. announced it has bolstered its Board of Directors with the appointments of Prof. Dr. Gerd Auffarth and Mr. Julian Gangolli. Prof. Dr. Auffarth is an internationally recognized ophthalmologist in the area of research and development as well as clinical care for patients. He currently serves as the Medical Director of Heidelberg University Eye Clinic. Prior to his appointment as Medical Director in 2011, he worked as a senior physician at the University Eye Clinic. He currently serves as the Director of the International Vision Correction Research Center (IVCRC) and the David J. Apple Laboratory for Ocular Pathology, which he has established in the University Eye Clinic and which are recognized worldwide in the field of implant and biomaterial research. He is a board member of the German (General Secretary) and the European Society for Cataract and Refractive Surgery and is considered one of the most experienced surgeons in cataract and corneal surgery. Mr. Gangolli is a leader in commercialization with a well-established track record and experience, having served as President of the North American Pharmaceutical division of Allergan, Inc. for 11 years where he was a member of the Executive Committee of Allergan. Mr. Gangolli most recently served as President, North America of Greenwich Biosciences, a GW Pharmaceuticals PLC. In addition to joining the Outlook Board of Directors, Mr. Gangolli currently serves as a Director on the Board of two publicly traded pharmaceutical companies: Revance Therapeutics and Krystal Biotech. Based upon the further recommendation of its Nominating Committee, the Board, effective upon the Effective Date, appointed Mr. Gangolli to serve as a member of both the Audit Committee of the Board, replacing Faisal G. Sukhtian, and on the Executive Committee of the Board, and Dr. Auffarth to serve as a member of the Nominating Committee, replacing Yezan Haddadin. Mr. Sukhtian and Mr. Haddadin will continue to serve as members of the Board and on any other respective committees of the Board to which they are appointed, for their respective terms.